Literature DB >> 1723407

Chemotherapy for advanced testicular cancer.

E P Fox1, P J Loehrer.   

Abstract

Testis cancer has become one of the most curable of all solid malignancies. More than 95% of patients should be cured with appropriate treatment and should have few long-term treatment-related side effects. Current chemotherapy for advanced testis cancer has resulted from an orderly sequence of chemotherapy trials that serves as a model for cancer chemotherapy development. Recent studies have defined the least therapy required to minimize toxicity while maintaining a high cure rate in "low-risk" patients. Further improvements are necessary in "high-risk" patients; evaluation of new regimens by means of randomized trials is essential.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723407

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  4 in total

Review 1.  Treatment intensification in disseminated germ-cell tumors.

Authors:  J Beyer; C Bokemeyer; H J Schmoll; W Siegert
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 2.  Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis.

Authors:  J P Donohue; E P Fox; S D Williams; P J Loehrer; T M Ulbright; L H Einhorn; T D Weathers
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

3.  Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals.

Authors:  G N Rudd; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Tuberculosis in postchemotherapy residual masses in germ cell tumor of the testis.

Authors:  Rajesh Bansal; Vinita Agrawal; Anil Mandhani
Journal:  Indian J Urol       Date:  2011-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.